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proteinase-induced destruction during immune complex-mediated
arthritis by preventing activation of pro-MMPs
P. L. E. M. van Lent, A. E. M. Holthuysen, A. Slo¨etjes, E. Lubberts and W. B. van den Berg
Department of Rheumatology, University Medical Centre Nijmegen, The Netherlands
Summary
Objective: To determine whether IL-4 protects against metalloproteinase-induced cartilage destruction during immune complex mediated
arthritis and to elucidate its mechanism.
Methods: Experimental immune complex arthritis (ICA) was raised by injecting lysozyme into the knee joints of mice which previously were
given anti-lysozyme antibodies. Three days before ICA induction, mice were injected into the right knee joint with either IL-4 expressing or
empty control recombinant human type 5 adenovirus. Joint inflammation and cartilage destruction (PG depletion, erosion) was measured by
histology of total knee joints. Aggrecan breakdown in cartilage caused by metalloproteinases (MMPs) was studied by immunolocalization
using anti-VDIPEN antibodies.
Results: Four days after ICA induction, histological analysis showed comparable exudate and infiltrate in both groups. Depletion of
proteoglycans as measured by loss of red staining was also comparable in both groups. IL-4 treatment inhibited MMP-mediated neoepitope
expression by 90%. Moreover, cartilage matrix erosion was evident in all animals (10 out of 10 mice) in the control group and significantly
diminished (only two out of ten mice) in the IL-4 treated group. Incubation of patellae with APMA, which activates latent MMPs resulted in
VDIPEN expression which was not significantly different from control ICA indicating that comparable amounts of latent pro-MMPs are present
in IL-4 treated arthritic knee joints.
Conclusion: This study indicates that during ICA, IL-4 largely prevents MMP-mediated aggrecan breakdown and severe cartilage erosion.
IL-4 does not inhibit production of latent MMPs by the chondrocyte but predominantly interferes with its activation. © 2002 OsteoArthritis
Research Society International
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Cartilage destruction is a major characteristic of rheuma-
toid arthritis (RA)1. An important group of enzymes capable
of cartilage destruction are metalloproteinases (MMPs).
These Zn-dependent endopeptidases are able to cleave
aggrecan and collagen type II, the main components
of cartilage2–3. Breakdown of these constituents may lead
to irreversible cartilage damage. During experimental
IC-mediated chronic arthritis, MMP-3 (stromelysin-1) and
MMP-13 (collagenase-3) appeared to be dominant MMPs
involved in erosion of cartilage matrix4. MMPs are made by
chondrocytes in a latent pro-form and released into the
matrix of the cartilage and their production is regulated by
IL-1 and TNF5–6. In addition, the latent pro-MMPs need
further activation to become able to breakdown cartilage
constituents. Many MMPs (-1,-2,-3,-7,-8,-9,-13 ) cleave
aggrecan between the G1 and G2 domain of the core
protein thereby generating specific neoepitopes ending at
specific AA sequence VDIPEN7–8. During experimental
arthritis, VDIPEN neoepitopes co-localize with other234eoepitopes generated by collagenase, the enzyme
esponsible for breakdown of collagen type II resulting in
rreversible cartilage destruction4.
IL-4 is one of the major cytokines which are able to
rotect against severe cartilage destruction during exper-
mental arthritis. IL-4 is a pleiotrophic cytokine mainly
roduced by Th2 CD4 positive T lymphocytes9 but also by
asophils10, mast cells11 and eosinophils12. As IL-4 is
lmost absent in the synovial fluid of RA knee joints13, this
ytokine may be a crucial therapeutic cytokine in blocking
evere cartilage destruction. In vitro studies have shown
hat IL-4 has the potential to antagonize mediators involved
n cartilage destruction14–17.
First IL-4 may inhibit severe cartilage destruction by
egulation of pro-MMP production18. In earlier studies we
ound that during collagen type II arthritis, IL-4 treatment
nhibited IL-1 mRNA levels in the synovium19–20.
nterleukin-1 (IL-1) is a dominant mediator in MMP-
ediated VDIPEN neoepitope expression and is a well-
nown inducer of pro-MMPs. Neutralization of interleukin-1
uring experimental chronic arthritis by IL-1 receptor
ntagonist completely prevented MMP-mediated neo-
pitope (VDIPEN) expression21. IL-4 over-expression in
he arthritic knee joint, strongly inhibited mRNA levels of
MP-3 in the inflamed synovium but interestingly MMP-3
evels were not lowered in the chondrocytes of the cartilage
ayer19. As MMP-3 is crucial in cartilage degradation within
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ANIMALS
Male normal C57BL/6 mice were obtained from Jackson,
U.S.A. They were fed a standard diet and tapwater
ad libitum. 10–12-weeks-old mice were used in the
experiments.INDUCTION OF EXPERIMENTAL ARTHRITIS
Experimental arthritis was induced as described ear-
lier31. In short, 3 g of PLL coupled lysozyme was injected
into the right knee joint of mice. These mice were given
200 l of specific antisera against lysozyme intravenously
4 h earlier. As control, the left knee joint was injected with
saline. Arthritis was evaluated using an arbitrary scale from
0–3 (0=no cells and 3=maximal amount of cells present
within the experiment).ADENOVIRAL VECTORS
Recombinant replication-deficient adenovirus
Ad5E1mIL-4 was generated by homologous recombination
after cotransfecting 293 cells with PACCMVmIL-4 and a
virus-rescuing vector pAdBHG10 as described32. Theempty recombinant replication–deficient adenovirus
Ad5del70-3 was used as a control vector throughout
the study. High titers of recombinant adenoviruses were
amplified, titered and stored as described33.BLOCKADE OF INTERLEUKIN-1
IL-1 was blocked using mini-osmotic pumps (Alzet
1007D; Alza, Palo Alto, CA) containing human IL-1 ra
(kindly provided by Synergen). Pumps were implanted into
the peritoneal cavity, 2 days before arthritis induction and
set to release 50 g of IL-1ra per hour for the next 7 days.
The steady state level of IL-1ra in the blood was 4.7 g/ml
from the first day after implantation as measured by
inhibition of IL-1 effects in an IL-1 sensitive assay34.HISTOLOGY
Knee joints were dissected and subsequently fixed in
phosphate buffered formalin (pH 7.4), decalcified in 5%
formic acid, and embedded in paraffin wax. Semi-serial
frontal whole knee joint sections (7 m) were stained with
hematoxylin to score inflammation and safranin-O and fast
green to score depletion of proteoglycans. Adjacent
sections were used for immunohistological staining of
inflammatory cells and the MMP-induced epitope. From
every knee joint, six cross-sections spaced 140 M were
investigated, giving a reliable mean of what is going on
inside the knee joint.DETERMINATION OF PROTEOGLYCAN DEPLETION AND MATRIX
EROSION
Loss of red staining from various cartilage layers (femur,
tibia and patella) was determined in total knee joint sections
stained with Safranin-O. Erosion was determined in total
knee joint sections stained with haematoxylin and eosin.
Erosion was detected as ruffling of the cartilage surface
and was only mild at day 4 after ICA induction. Various
cartilage surfaces (e.g. medial and lateral tibia, medial and
lateral femur, patella and femur) were investigated. The
severity of erosion was calculated using an arbitrary scale
from 0–3. Loss of red staining was also scored using an
arbitrary scale from 0–3. Normal cartilage and cartilage
fully depleted from PG was taken as 0 and 3 value
respectively.IMMUNOLOCALIZATION OF MMP-INDUCED NEOEPITOPE
For immunohistochemical analysis, sections were
deparaffinized, rehydrated and digested with chondro-
itinase ABC (Sigma, 0.25 U/ml, 0.1 M Tris-HCL pH 8.0) for
1 h at 37°C, to remove chondroitine sulphate from the
proteoglycans. Sections were then treated with 1% H2O2 in
methanol for 20 min and subsequently 5 min with 0.1%
(v/v) triton X-100 in PBS. After incubation with 1.5% (v/v)
normal goat serum for 20 min, sections were incubated
with affinity-purified anti-VDIPEN IgG overnight at 4°C.
These antibodies were kindly given to us by Drs Irwin
Singer and Ellen Bayne (Merck Rahway, NJ) and have
been extensively characterized before35. In addition, sec-
tions were incubated with biotinylated goat antirabbit IgG
and detected using avidine-peroxidase staining (Elite kit,these models22, this may indicate that IL-4, has no effect on
pro-MMP-3 released by the chondrocyte.
Apart from regulation of the production of pro-MMPs,
IL-4 may also be involved in activation of the latent pro-
MMP present within the cartilage matrix into their active
form. Mechanisms needed for activation of latent MMPs
released in the cartilage matrix may be enzymes such as
plasmin23, elastase24 and/or oxygen radicals25–28. Immune
complexes are crucial in this activation step since MMP-
mediated neoepitopes were only found in those arthritis
models in which ICs were present29. Within the joint, ICs
mediate their effects by activatory Fc receptors and expres-
sion of MMP-mediated neoepitopes was completely absent
after induction of IC-mediated arthritis in knee joint of
FcR-deficient mice. However, latent pro-MMPs were still
abundantly present within the cartilage matrix of the
arthritic joints30. Blockade of MMP-mediated cartilage
destruction thus may interfere with either pro-MMP acti-
vation mechanisms and/or by mechanisms preventing the
generation of pro-MMPs.
In the present study, we investigated by which of the two
mechanisms mentioned above IL-4 protects cartilage
destruction during experimental arthritis. As ICs are crucial
in pro-MMP activation we used an experimental arthritis
model induced by local generation of immune complexes.
Immune complex arthritis (ICA) was induced by injection of
PLL lysozyme into the knee joints of C57 BL/6 mice which
previously were given antilysozyme specific antibodies31. A
moderate joint inflammation is induced followed by destruc-
tion of the cartilage layers. The latter is mediated by
metalloproteinases as seen by VDIPEN neoepitope
expression eventually leading to mild cartilage erosion.
IL-4 over-expression was achieved by local injection of
adenoviral IL-4 in the knee joint prior to arthritis induction.
Our results indicate that the major function of IL-4 within
this model is blocking the activation step for latent
MMPs within the cartilage layer rather than inhibiting the
generation of pro-MMPs.
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dase product was done using nickel enhancement and
counterstaining was done with orange G (2%) for 5 min.IMMUNOLOCALIZATION OF INFLAMMATORY CELLS
The presence of polymorphonuclear cells (PMNs) was
analysed on knee joint sections. Briefly, sections were
deparaffinized, and pre-incubated for 15 min at RT with
20% normal rabbit serum. Thereafter sections were incu-
bated with NIMPR14 (25 to 30 kDa epitope mainly on
neutrophils) antibody for 1 h36. After incubation with the
second antibody rabbit antirat peroxidase for 30 min, the
sections were stained with hematoxylin for 30 s. As a
negative control, sections were incubated with normal rat Ig
instead of NIMPR14 antibodies.IN VITRO CARTILAGE ASSAY
Whole murine patellae were isolated with a minimal
amount of surrounding tissue. Patellae were cultured in
96-well microtiter plates (1 patella per well) in RPMI
(GIBCO/BRL, Life Technologies) (supplemented with
0.25 g/ml) IGF with or without 1 mM p-aminophenyl-
mercuric acetate (APMA) and the plate was incubated at
37°C overnight. Subsequently the patellae were washed in
0.7% NaCl, embedded in OCT and then frozen in liquid
nitrogen.DETERMINATION OF IL-4 AND IL-1 PROTEIN
To determine the levels of IL-4 and IL-1 in patella
washouts, patellae from arthritic joints were isolated in a
standard manner as described earlier37. Patellae with sur-
rounding tissue were incubated in RPMI 1640 medium with
0.1% BSA, gentamicin (50 g/ml), and L-glutamin (2 mM)
(200 l per patella) for 1 h at RT. After the supernatant was
harvested, IL-4 and IL-1 was tested by ELISA. Briefly,
ELISA plates were coated with the capture antibody (3 g/
ml) by overnight incubation at 4°C in carbonate buffer
(pH 9.6). Non-specific binding sites were blocked by 1 h
incubation at 37°C with 1% BSA in PBS/Tween. The
supernatants from the patella cultures were tested by 3 h
incubation at 37°C. The plates were then incubated for
1.5 h at 37°C with the biotinylated second Ab followed
by 30 min incubation at 37°C with streptavidine-poly-
peroxidase conjugate. Bound complexes were detected by
reaction with OPD (ortho-phenylenediamine) and H2O2.
Absorbance was measured at 492 nM using an ELISA
plate reader (Titertek Multiscan MCC/340). The cytokine
concentration in the samples was calculated as pg/ml using
recombinant murine IL-4 or IL-1 as a standard. The
sensitivity of the IL-4 ELISA is 10 pg/ml whereas for IL-1
this is 20 pg/ml.ResultsCOURSE OF PROTEOGLYCAN DEPLETION AND MMP-MEDIATED
CARTILAGE DESTRUCTION IN VARIOUS CARTILAGE LAYERS OF
THE KNEE JOINT DURING ICA
To characterize cartilage destruction during arthritis
elicited by immune complexes (ICA), loss of proteoglycans
and expression of VDIPEN was determined in cartilagelayers of femur and patella at several time-points after
induction of ICA (days 1, 2 and 4). Depletion of PG was
measured by image analysis using total knee joint sections
stained with Safranin-O. Loss of red staining was already
maximal at day 1 [Fig. 1(a)]. In addition, we determined the
amount of MMP-mediated neoepitope (VDIPEN) in the
cartilage layers. VDIPEN is a marker of MMP-mediated
destruction and is coupled to breakdown of collagen type II
resulting in severe cartilage destruction4. VDIPEN staining
was low at day 1, gradually increasing untill day 4
[Fig. 1(b)]. These results indicate that during ICA, PG
depletion and MMP-mediated cartilage destruction may
develop independently in analogy to what we found earlier
in the more chronic antigen-induced arthritis model29. To
further investigate the effect of IL-4 on VDIPEN generation
ICA day 4 was chosen.0
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Fig. 1. Immune complex arthritis was induced in knee joints of
C57BL/6 mice. At day 1, 2 and 4 after induction of arthritis, knee
joints were studied for PG depletion and MMP-mediated
neoepitope expression. PG depletion was studied as loss of red
staining from Safranin-O stained sections. Loss of red staining was
scored using an arbitrary scale of 0–3. MMP-mediated neoepitope
expression (VDIPEN) was determined with immunostaining and
measured using image analysis. For every knee joint, three
sections were measured for area of immunostaining and the mean
of these determinations is depicted as one data point. Various
cartilage layers at different positions in the knee joint were
measured (MT=medial tibia; MF=medial femur; LT=lateral tibia;
LF=lateral femur; F=femur and P=patella) and the mean was
expressed. Note that maximal staining of PG depletion was
already found at day 1, whereas maximal MMP-mediated
neoepitope expression was found not earlier than day 4.ADENOVIRAL VECTOR MEDIATED IL-4 EXPRESSION IN ICA KNEE
JOINTS
To evaluate the effect of IL-4 on MMP-mediated carti-
lage destruction, IL-4 was locally induced with IL-4
adenovirus. 6 l containing 107 pfu of Ad5E1mIL-4 (IL-4
vector) or Ad5del70-3 (control vector) was injected in the
knee joint of mice, 3 days prior to induction of ICA. Four
days after ICA induction, IL-4 protein levels were
measured in washouts of joint tissue using an IL-4
specific ELISA. Between 650 and 750 pg/ml IL-4 was
found on day 4 after ICA induction. No IL-4 levels were
detectable in the circulation (detection limit 10 pg/ml).
Injection of 107 pfu of Ad5mEIL-4 in normal knee joints
Osteoarthritis and Cartilage Vol. 10, No. 3 237only induced minor joint inflammation not significantly
different from the control vector. Furthermore no IL-4 was
noted in naive joints, inflamed joints or inflamed joints
injected with the control vector (data not shown).IL-4 INHIBITS VDIPEN EXPRESSION AND LARGELY PREVENTS
CARTILAGE EROSION BUT HAS NO EFFECT ON PROTEOGLYCAN
DEPLETION
First, we studied whether IL-4 alters the first stage of
cartilage destruction. Depletion of proteoglycans was
determined by measuring loss of red staining from
Safranin-O stained total knee joint sections. IL-4 itself
induced minimal depletion of proteoglycans in naive knee
joints (Table I). Induction of ICA in the control virus treated
group elicited a marked depletion of proteoglycans from the
cartilage matrix. After over-expression of IL-4 in arthritic
knee joints, marked depletion of proteoglycans was still
seen, not different from the control group. This indicates
that IL-4 has no effect on early cartilage proteoglycan loss
(Table I).
Second, we investigated whether IL-4 altered the subse-
quent stage of cartilage destruction. Injection of either
control or IL-4 virus in naive knee joints did not induce
MMP-mediated neoepitopes (VDIPEN). In contrast, arthritis
induction in knee joints previously injected with the control
virus, generated prominent VDIPEN expression in the
cartilage surfaces of arthritic knee joints [Table I, Fig. 2(c)
vs (d)]. VDIPEN expression was highest in the lateral tibia
and femur. Interestingly, in IL-4-virus treated arthritic knee
joints, VDIPEN neoepitopes were 90% lower [Table I, Fig.
2(b) and (c) vs (d)]. Some VDIPEN staining was observed,
but only at the edges of the femur.
As VDIPEN expression has been shown to be related to
irreversible cartilage surface erosion4, we additionally
determined ruffling of the cartilage surface at day 7 after
induction of arthritis. ICA induced in knee joints of C57BL/6
mice only shows mild erosions at this time-point. In the
control vector treated arthritic knee joints, erosions were
mainly found in the femural surfaces and were present in all
animals examined [Table I, Fig. 2(e)]. In the viral-IL-4
treated arthritic knee joints, erosion was significantly dimin-ished and only found in two out of 10 animals, indicating
that apart from inhibiting VDIPEN expression, IL-4 also
protects against cartilage matrix erosion [Table I, Fig. 2(e)
vs (f)].Table I
Effect of IL-4 over-expression on cartilage destruction (PG depletion, VDIPEN and matrix erosion) at day 4 after
ICA induction
PG depletion VDIPEN staining Matrix erosion
Ad5del70-3 virus 0.4 (0.4) 0 0
Ad5E1mIL-4 virus 0.7 (0.3) 0 0
Ad5del70-3 virus+ICA 2.6 (0.5) 2.3 (0.8) 0.9 (0.4)
Ad5E1mIL-4 virus+ICA 2.4 (0.7) 0.2 (0.4)* 0.2 (0.3)*
Treatment of IL-4 on various parameters of cartilage destruction (PG depletion, MMP-mediated neoepitope
expression and matrix erosion) was determined in cartilage layers of total knee joint sections, 4 days after
induction of ICA. 6 l containing 107 pfu of Ad5del 70-3 or Ad5E1mIL-4 was injected 3 days before induction of
ICA. All cartilage destruction parameters were scored using an arbitrary scale of 0–3. For every knee joint
three sections were measured. PG depletion was measured as loss of red staining in various cartilage layers
(femur, tibia, patella) stained with Safranin-O. (0=no depletion; 1=minor depletion; 2=moderate depletion;
3=maximal depletion). VDIPEN immunostaining in femur, tibia and patellae was measured (0=no VDIPEN;
1=minor VDIPEN; 2=moderate VDIPEN; 3=maximal VDIPEN). Erosion of the cartilage surface was defined
as ruffling of the cartilage surface. (0=no erosion; 1=minor erosion; 2=moderate erosion; 3=maximal erosion).
The mean of these measurements is depicted as one data point. Note that comparable loss of red staining of
cartilage was found in IL-4 and control virus treated arthritic joints. IL-4 treatment almost completely blocked
VDIPEN expression. Erosions although mild at that time-point were significant less in the IL-4 treatment group.
Data are expressed as the mean and S.D. of 12 mice. Data were tested using the Mann–Whitney U test.
*P<0.05.LOCAL IL-4 EXPRESSION HAS NO EFFECT ON JOINT INFLAMMATION
DURING ICA
Inflammatory cells are important producers of factors
which either generate pro-MMP production (such as IL-1)
or activate pro-MMPs (such as neutrophil elastase). Differ-
ences in the amount and/or type of inflammatory cells in the
arthritic knee joint caused by the IL-4 treatment may alter
the generation of MMP-mediated cartilage destruction. The
amount of cells present in the synovium (infiltrate) and in
the joint cavity (exudate) were examined in total knee joints
of mice stained with hematoxylin/eosin. IL-4 over-
expression in the knee joint of naive mice gave rise to only
minor infiltrate (0.9±0.3) and exudate (0.1±0.2) on day 4.
Even less infiltrate (0.5±0) was observed 7 days after
injection of the control virus.
Local injection of the control virus into the knee joint
followed by a 4-day lasting IC-arthritis showed a moderate
inflammation [infiltrate (1.9±0.4) and exudate (1.9±0.5]. A
single injection of IL-4 virus showed a somewhat higher
infiltrate, although not reaching significance (2.6±0.7 vs
1.9±0.5) whereas exudate was comparable to that in
control arthritic knee joints (1.8±1.2 vs 1.9±0.5) (Table II).
In addition, we investigated whether the type of inflam-
matory cell (polymorphonuclear cell and monocytes) was
altered by the IL-4 treatment. Total knee joint sections
were immunostained with anti-NIMPR14, an antibody
which specifically binds to a 90 kD membrane protein
specific for PMNs36. At day 4 ICA most of the inflamma-
tory cells found in the exudate appeared to be PMNs,
whereas in the infiltrate monocytes were the dominant cell
type. A comparable ratio PMN/monocytes was found in
arthritic knee joints either injected with ad5mIL-4 or the
ad5del170-3 control vector (Table II). These results sug-
gest that neither number nor type of inflammatory cell is
responsible for the protecting effect of IL-4 in neoepitope
generation.
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Fig. 2. VDIPEN expression in various cartilage layers of arthritic knee joint (4 days after ICA induction), 7 days after intraarticular injection
of control Ad5del 70-3 (a) or Ad5E1mIL-4 (b). VDIPEN expression was measured using image analysis (area of VDIPEN staining in the
cartilage). Note that VDIPEN epitope expression in all examined cartilage layers in the IL-4 treated group was almost absent. Photographs
show prominent VDIPEN staining in the femur of control (c) but not in the IL-4 treated ICA knee joints (d). Furthermore moderate cartilage
erosion of the femur in the control arthritic (e); (see arrows) was observed which was absent in the IL-4 treated arthritic knee joints (f).
(Original magnification ×200.) MT=medial tibia; MF=medial femur; LT=lateral tibia; LF=lateral femur; P=patella; F=femur.INTERLEUKIN-1 DETERMINES INDUCTION OF MMP-MEDIATED
NEOEPITOPE FORMATION DURING ICA
In previous studies we found that during T-cell-mediated
antigen-induced arthritis, IL-1 is the dominant cytokine
involved in generation of MMP-mediated neo-epitopes. We
first investigated the significance of IL-1 in MMP-mediated
cartilage destruction within the ICA model. IL-1 formed
during the first four days of ICA was neutralized using
human IL-1ra released by osmotic pumps implanted intra-
peritoneally. Neutralization of IL-1 fully prevented VDIPEN
expression whereas prominent VDIPEN expression was
observed in the cartilage layers of the control arthritic joint
(Fig. 3). Proteoglycan depletion was comparable in both
groups at this time-point (data not shown). To furtherinvestigate whether cartilage from IL-1 blocked arthritic
knee joints does contain latent pro-MMPs, patellae were
isolated and treated with APMA, a well-known activator of
latent MMPs. No rise in VDIPEN was found. As a postive
control, high expression was found after APMA activation of
patellae previously incubated with IL-1 (data not shown).
These results indicate that within ICA, IL-1 is the crucial
cytokine regulating the generation of MMP-mediated
neoepitopes.
As IL-1 was found to be the dominant cytokine involved
in MMP-mediated cartilage destruction within this model,
we additionally measured IL-1 in washouts of control and
IL-4-virus treated arthritic knee joints. Using a specific
ELISA, we found that IL-1 levels were only 9% lower in
the washouts of the IL-4 treated arthritic synovial specimen
Osteoarthritis and Cartilage Vol. 10, No. 3 239if compared to control virus (control virus 1089 pg/ml vs
IL-4 virus 988 pg/ml) indicating that IL-4 has no significant
effect on local IL-1 production.LOCAL IL-4 OVER EXPRESSION DOES NOT PREVENT PRO-MMP
GENERATION
As IL-1 is not significantly lowered in IL-4 treated arthritic
knee joints, this suggests that pro-MMP production in the
cartilage may not be diminished by the IL-4 treatment. To
verify this, the pro-MMP content of patellae derived from
day 4 arthritic joints were examined by activating them
with APMA. Patellae derived from naive knee joints
either injected with control or IL-4 virus showed no VDIPEN
upon stimulation with APMA (data not shown). Patellae
derived from arthritic knee joints earlier injected with the
control virus, showed prominent VDIPEN expression
[Fig. 4(a),(b)]. Activation of these patellae by APMA showed
a strong elevation of VDIPEN staining (192%), indicating
that four days after ICA induction, only about 30% of the
pro-MMP content in the cartilage matrix becomes activated
[Fig. 4(a),(b) vs (c)]. If arthritic knee joints were previously
injected with the IL-4 virus, VDIPEN expression wasreduced by 80% [Fig. 4(a),(b) vs (c)]. Strikingly, APMA
activation of these patellae showed a tremendous raise
in VDIPEN expression (1176%) indicating that the
cartilage matrix did contain large amounts of latent MMPs
[Fig. 4(a),(d) vs (e)].
Comparison of the absolute amounts of VDIPEN expres-
sion in APMA activated patellae derived from control or IL-4
virus treated arthritic joints showed that VDIPEN expres-
sion differed only for 13%. To substantiate this finding, we
also incubated patellae with lower concentrations of APMA.
We found that suboptimal concentrations of APMA (0.1 and
0.05 mM), induced lower VDIPEN expression. Again only
15% difference was found between the two groups indicat-
ing that IL-4 treatment only slightly alters the amount of
pro-MMP present within the arthritic cartilage matrix (data
not shown). IL-4 seems therefore predominantly to inhibit
mechanisms regulating activation of pro-MMPs.Table II
Effect of IL-4 expression on joint inflammation at day 4 after ICA induction
Infiltrate
(amount)
Exudate
(amount)
Infiltrate (%) Exudate (%)
PMN MONO PMN MONO
Ad5del70-3 virus 0.5 (0) 0.1 (0.2) N.D. N.D.
Ad5E1mIL-4 virus 0.9 (0.3) 0.1 (0.2) N.D. N.D.
Ad5del70-3 virus+ICA 1.9 (0.4) 1.9 (0.5) 33–37 63–67 58–74 26–42
Ad5E1mIL-4 virus+ICA 2.6 (0.7) 1.8 (1.2) 23–29 71–77 50–60 40–50
The amount of inflammatory cells in the synovium (infiltrate) and in the joint cavity (exudate) was determined
4 days after induction of ICA. In these knee joints, 107 pfu of Ad5del 70-3 or Ad5E1mIL-4 was injected 3 days
before induction of ICA. Total knee joints were stained with haematoxylin/eosin. For every knee joint three
sections were measured. The amount of cells was scored using an arbitrary scale from 0–3 (0=no cells; 1=minor
amount of cells; 2=moderate amount of cells; 3=maximal amount of cells). The type of cell was determined with
immunostaining using a PMN-specific antibody (NIMPR14). The mean of these measurements is depicted as one
data point. Comparable amount of infiltrate and exudate was found in both Ad5del 70-3 or Ad5E1mL-4 injected
arthritic knee joints. The ratio of PMN/monocytes was not significantly different in both groups. Two independent
experiments were done. Data are expressed as the mean and S.D. of 12 mice. Data were tested using the
Mann–Whitney U-test. ND=not done.0
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Fig. 3. Immune complex arthritis was induced in knee joints of control and IL-1ra treated C57BL/6 mice. At day 4 after arthritis induction, knee
joints were studied for VDIPEN expression. The area of positive immunostaining in the cartilage layers was measured using image analysis.
For every knee joint, 3 sections were measured for area of immunostaining and the mean of these determinations is depicted as one data
point. Various cartilage layers at different positions in the knee joint were measured (MT=medial tibia; MF=medial femur; LT=lateral tibia;
LF=lateral femur). In each group six animals were tested. Note that neutralization of IL-1 almost completely prevented VDIPEN staining.Discussion
In the present study we show that over-expression of
IL-4 in an IC-mediated arthritic knee joint protected the
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Fig. 4. Patellae were taken at day 4 after ICA induction. Three days prior to ICA induction, knee joints were injected with either Ad5del 70-3
or Ad5E1mIL-4 virus. Patellae were incubated with or without APMA to activate latent matrix metalloproteinases (pro-MMPs). Cartilage
sections were stained with anti-VDIPEN. Immunostaining was measured using image analysis. (a) For each patella, 3 sections were
measured and the mean of these determinations is depicted as 1 data point. Data were evaluated using the Mann–Whitney U-test. *P<0.05.
Photographs show a patella derived from ICA day 4 (Ad5del70-3) without APMA (b), ICA day 4 (Ad5del70-3) with APMA (c), ICA day 4
(Ad5E1mIL-4 ) without APMA (d), and ICA day 4 (Ad5E1mIL-4) with APMA (e). Original magnification ×200.cartilage matrix from MMP-mediated destruction and matrix
erosion.
Cartilage destruction is a major feature during ICA and is
characterized by two distinct processes. The first phase is
characterized by loss of proteoglycans from the cartilage
matrix and this is mediated by aggrecanase resulting in
NITEGE neoepitopes38–39. IL-4 treatment of the arthritic
knee joint had however no effect on loss of proteoglycans,
indicating that IL-4 does not interfere with the first stage of
cartilage destruction, the aggrecanase-mediated PG loss.
The second stage which develops later during arthritis in
this acute model, reached maximal values around day 4
and was almost completely blocked by local IL-4 treatment.
This stage is characterized by the generation of VDIPEN
epitopes which is related to matrix erosion but uncoupled to
PG depletion. This is in line with earlier studies done in themore chronic antigen-induced arthritis in which we found
that PG depletion was already evident at day 1, whereas
VDIPEN staining was detected not earlier than 5 days after
arthritis induction29.
IL-4 is a multifunctional cytokine which has blocking
effects on MMP-mediated cartilage destruction14–16,19–20
which might be explained in various ways. One explanation
may be that IL-4 alters the inflammatory response within
the arthritic knee joint. In a previous study we found that
local IL-4 treatment in the knee joints of mice suffering from
collagen type II arthritis, alters the amount and composition
of the inflammatory response19. As collagen type II is T-cell
driven and IL-4 inhibits T helper responses against collagen
type II, this may well explain lowering MMP-mediated
cartilage destruction found within that study. In the present
study we show that using a non-T-cell-mediated IC-arthritis,
Osteoarthritis and Cartilage Vol. 10, No. 3 241high amounts of IL-4 do not significantly change either the
amount or the inflammatory cell type within the arthritic
knee joints. IL-4 has been shown to be a chemoattractant
for monocytes40, macrophages41, eosinophils42 and fibro-
blasts43. However, if IL-4 was over-expressed in naive
knee joints, only minimal amounts of monocytes/
macrophages migrated to the joint. The number of these
cells was low if compared with the number of cells which
infiltrate the knee joint as a result of experimental arthritis.
This suggests that IL-4 has only minimal effects on comp-
lement activation and IL-1-mediated chemokine production,
factors which have been shown to be crucial in regulating
IC-mediated arthritis31.
A second explanation for the blocking activity of IL-4 in
MMP-mediated cartilage destruction may be an inhibiting
effect on IL-1 production since in this model, IL-1 is the
crucial cytokine involved in the manufacture and release of
pro-MMPs by the chondrocyte44. As a control we showed
that blockade of IL-1, using IL-1 receptor antagonist, com-
pletely blocked MMP mediated VDIPEN expression at day
4 after ICA induction. Similar results of IL-1ra were earlier
found in T-cell-driven antigen-induced arthritis21. IL-4 treat-
ment somewhat decreased IL-1 levels in the washouts of
arthritic joints. Although IL-4 has been shown to stimulate
IL-1ra production45, this may be too low to efficiently block
IL-1 function. In line with this, patellae derived from IL-4
treated arthritic joint, showing almost no VDIPEN staining,
developed prominent VDIPEN expression after activation
by APMA, indicative of high levels of IL-1-induced pro-
MMPs. The absolute amount of VDIPEN measured was
only 13% less than that measured in APMA activated
patellae from arthritic controls. This suggests that although
IL-1 levels were somewhat (9%) lower in the IL-4-treated
arthritic knee joints, the remaining IL-1 seemed still suf-
ficient for almost maximal (90%) production of pro-MMPs
in the cartilage layers.
Apart from VDIPEN expression, erosions of the cartilage
surface, although mild at day 4 after arthritis induction,
were significantly decreased in the IL-4-treated arthritic
knee joints. MMP-mediated neoepitope expression is
related to degradation of the collagen network4.
Stromelysin-1 (MMP-3) has been shown to form a crucial
enzyme involved in activation of collagenase responsible
for collagen type II degradation . Earlier studies revealed
that VDIPEN neoepitopes and collagenase-induced
neoepitopes co-localized in the cartilage matrix during
experimental arthritis4. Furthermore both VDIPEN expres-
sion and erosion of the cartilage matrix were completely
blocked after induction of immune complex arthritis in
MMP-3 deficient mice4. In vitro studies have shown that
IL-4 is able to suppress IL-1-induced MMP-3 mRNA in
cartilage14–15. In contrast, however, in vivo studies showed
that adenoviral IL-4 overexpression in the knee joint,
although inhibiting mRNA levels of various factors like IL-1,
TNF and MCP-1, failed to inhibit mRNA levels of MMP-319
in the cartilage layer of the knee joint.
The above results suggest that IL-4 does not inhibit
MMP-mediated cartilage destruction by lowering the pro-
MMP release into the cartilage layer but probably by
inhibiting synovial factors involved in activation of pro-
MMPs. During arthritis, the load of latent MMPs in the
cartilage matrix is high and only part of the latent MMPs
present were in an activated state. After 4 days of joint
inflammation only 30% of the pro-MMPs present in the
patellae were activated (as compared to APMA activated
patellae). Mechanisms involved in activation of pro-MMPsrather than factors which regulate its expression may be
the crucial target of IL-4.
Many mechanisms may be involved in activation of latent
MMPs, such as enzymes23–25 and oxygen radicals26–28.
IL-4 may inhibit production of enzymes produced by syn-
ovium like stromelysin or inflammatory cells like elastase
which both have been shown to be potent activators
of pro-MMPs4,46. Intriguigingly VDIPEN expression is
observed only in arthritis models in which immune com-
plexes are present. If arthritis is induced by bacterial or
yeast cell walls, no VDIPEN neoepitopes are found
although severe joint inflammations are observed29.
Immune complexes communicate with leucocytes via Fc
receptors. A previous study revealed that experimental
arthritis induced in FcR -chain KO mice which lack func-
tional FcR failed to develop VDIPEN expression30. As IL-4
is the most potent cytokine down-regulating FcR expres-
sion on leucocytes (paper in preparation), IL-4 treatment
probably prevents IC activation of these cells thus inhibiting
the load of activators of pro-MMPs.
During RA the synovium becomes heavily thickened,
mainly due to accretion of macrophages in the joint. The
amount of macrophages has been shown to correlate well
with cartilage destruction47. Apart from reduction of
destructive cytokines and lowering of TH1 reactivity, local
treatment with IL-4 may result in lowering activators of
pro-MMPs produced by activated macrophages. As such,
IL-4 provides a potent therapy to prevent MMP-mediated
cartilage destruction and subsequent cartilage erosion.Acknowledgments
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